Management

Mr. Young is a US-based long-time executive in the biopharmaceuticals industry.  He is the former President and CEO of Osteologix, Inc, a global biopharmaceutical company, which is currently based in Ireland.  He joined Osteologix in May 2007 and led the multinational company’s efforts to develop a novel therapy for osteoporosis which resulted in a global licensing deal with Servier Laboratories, a private French pharmaceutical company.  He remains on the Board of Directors for Osteologix Holdings Ltd.

Prior to joining Osteologix, Mr. Young held a number of senior executive positions with publicly traded biotechnology companies. From 2004-2007 he was with Insmed Inc., where he served as executive vice president and chief business officer. While at Insmed, Mr. Young led the successful launch and commercialization of a novel biologic growth hormone therapy and assisted the company in raising over $100 million to further the company objectives and expand the drug’s research pipeline to other diseases. Previously, Mr. Young served as president and chief operating officer at several biotechnology companies in the San Francisco Bay area. While serving as a Vice President at Neurex Pharmaceuticals, Mr. Young was a key member of the negotiating team that successfully sold Neurex to Elan for over $700 million.

Dr. Harper has served as Chief Scientific Officer of AmpliPhi Biosciences since the January 2011 acquisition of Biocontrol Ltd. by Targeted Genetics Corporation. Dr. Harper founded Biocontrol in 1997.  He previously served as leader of the herpes virus research group in the Department of Virology at St. Bartholomew’s Medical School, joining the faculty in 1991 as a Lecturer in Molecular Virology.  Dr. Harper received his B.Sc. in microbiology and virology at the University of Warwick and Ph.D. at the University of Newcastle-upon-Tyne studying viral genetics.  He he carried out post-doctoral work at St. Bartholomew’s Medical School in London and at the University of Iowa.